诺提亚可以通过准尖端蛋白来抑制SARS-CoV-2的进入
Taizhen Liang1,2, Shiqi Xiao1, Ziyao Wu3
1Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou 510005, China.
Viruses
|August 26, 2023
概括
提亚衍生物对SARS-CoV-2及其变种,包括Omicron.表现出强大的抑制作用. 这些药物可能为当前和未来的冠状病毒感染提供广泛的治疗.
科学领域:
- 病毒学 病毒学
- 药物发现 药物发现 药物发现
- 药用化学 医学化学
背景情况:
- 严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2) 的出现造成了全球卫生危机.
- 新的SARS-CoV-2变种和其他新出现的冠状病毒需要广泛的治疗方法.
- 现有的治疗方法需要用有效和多功能抗病毒药物来增强.
研究的目的:
- 识别具有针对SARS-CoV-2及其变种的强有力的抗病毒活性的美国FDA批准的药物.
- 为了研究表亚衍生物作为广泛的抗病毒药物的潜力.
- 阐明西介导的SARS-CoV-2抑制的作用机制.
主要方法:
- 对美国FDA批准的药物的抗病毒活性进行查.
- 测试抑制伪型的SARS-CoV-2,令人担忧的变种 (Delta,Omicron亚系XBB,BQ.1.1),SARS-CoV和MERS-CoV.
- 机理学研究,以确定由表亚酶向的病毒感染的阶段.
主要成果:
- 提亚衍生物对SARS-CoV-2伪病毒和各种变体进行了强有力的抑制.
- 观察到对SARS-CoV和MERS-CoV伪病毒的抑制活性.
- 提亚似乎通过准尖端蛋白来抑制SARS-CoV-2感染,从而可能阻止其分裂.
结论:
- 氨酸对SARS-CoV-2及其变体和其他人类冠状病毒具有广泛的抗病毒活性.
- 提亚是一种有前途的化合物类别,可用于开发新型抗病毒疗法.
- 对表亚的进一步研究可能会导致当前和未来的冠状病毒爆发的有效治疗方法.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
332
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
332
Antipsychotic Drugs: Typical and Atypical Agents
244
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
244
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
606
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
606
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
341
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
341
Antiepileptic Drugs: GABAergic Pathway Potentiators
453
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
453


